Polyserase-1/TMPRSS9 induces pro-tumor effects in pancreatic cancer cells by activation of pro-uPA

Fontanil,Tania; Mohamedi,Yamina; Esteban,Manuel M.; Obaya,Alvaro J.; Cal,Santiago

doi:10.3892/or.2014.3146

Polyserase-1/TMPRSS9 induces pro-tumor effects in pancreatic cancer cells by activation of pro-uPA

Authors:
- Tania Fontanil
- Yamina Mohamedi
- Manuel M. Esteban
- Alvaro J. Obaya
- Santiago Cal
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, University of Oviedo, 33006 Oviedo, Asturias, Spain, University Institute of Oncology of Principado de Asturias (UOPA), University of Oviedo, 33006 Oviedo, Asturias, Spain
Published online on: April 23, 2014 https://doi.org/10.3892/or.2014.3146
Pages: 2792-2796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polyserase-1/TMPRSS9 is a type II transmembrane serine protease showing a complex molecular architecture characterized by the presence of three tandem serine protease domains in its amino acid sequence. This protease is widely expressed in mouse and human tissues, however, its functional significance is unknown in both normal and pathological conditions. In the present study, we evaluated the possible role of polyserase-1 in cancer progression. First, we showed that polyserase-1 increased the invasive capacities of PANC-1 and SK-PC-3 pancreatic cancer cells. Moreover, the presence of polyserase-1 enhanced anchorage-independent growth and diminished the adhesion capability of PANC-1 cells to different extracellular matrix components. These effects were mediated by the efficient conversion of pro-uPA to active uPA and high phosphorylation levels of ERK detected in the PANC-1 cells expressing exogenous polyserase-1. Collectively, our data suggest that polyserase-1 may be involved in cancer progression and, similarly to what has been proposed for the closely related serine proteases matriptase and TMPRSS4, inhibition of TMPRSS9 activity may contribute to the inhibition of tumor growth.

View Figures

View References

1	Hornebeck W, Emonard H, Monboisse JC and Bellon G: Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol. 12:231–241. 2002. View Article : Google Scholar : PubMed/NCBI
2	Wilkins-Port CE, Higgins SP, Higgins CE, Kobori-Hotchkiss I and Higgins PJ: Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: functional interactions between the serine rrotease and matrix metalloproteinase cascades. Biochem Res Int. 2012:4543682012.
3	Netzel-Arnett S, Hooper JD, Szabo R, et al: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
4	Lu D, Yuan X, Zheng X and Sadler JE: Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain. J Biol Chem. 272:31293–31300. 1997. View Article : Google Scholar : PubMed/NCBI
5	Gladysheva IP, Wang D, McNamee RA, et al: Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension. 61:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
6	Folgueras AR, de Lara FM, Pendas AM, et al: Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood. 112:2539–2545. 2008. View Article : Google Scholar : PubMed/NCBI
7	Guipponi M, Tan J, Cannon PZ, et al: Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss. Am J Pathol. 171:608–616. 2007. View Article : Google Scholar : PubMed/NCBI
8	Wu Q: Type II transmembrane serine proteases. Curr Top Dev Biol. 54:167–206. 2003. View Article : Google Scholar : PubMed/NCBI
9	Webb SL, Sanders AJ, Mason MD and Jiang WG: Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci. 16:539–552. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hashimoto T, Kato M, Shimomura T and Kitamura N: TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J. 277:4888–4900. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wu Q and Parry G: Hepsin and prostate cancer. Front Biosci. 12:5052–5059. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chen CH, Su KY, Tao MH, et al: Decreased expressions of hepsin in human hepatocellular carcinomas. Liver Int. 26:774–780. 2006. View Article : Google Scholar : PubMed/NCBI
13	Szabo R and Bugge TH: Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol. 40:1297–1316. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kosa P, Szabo R, Molinolo AA and Bugge TH: Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene. 31:3679–3695. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lang JC and Schuller DE: Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer. 84:237–243. 2001. View Article : Google Scholar : PubMed/NCBI
16	Viloria CG, Peinado JR, Astudillo A, et al: Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin. Br J Cancer. 97:201–209. 2007. View Article : Google Scholar : PubMed/NCBI
17	Cal S, Quesada V, Garabaya C and Lopez-Otin C: Polyserase-I, a human polyprotease with the ability to generate independent serine protease domains from a single translation product. Proc Natl Acad Sci USA. 100:9185–9190. 2003. View Article : Google Scholar : PubMed/NCBI
18	Okumura Y, Hayama M, Takahashi E, et al: Serase-1B, a new splice variant of polyserase-1/TMPRSS9, activates urokinase-type plasminogen activator and the proteolytic activation is negatively regulated by glycosaminoglycans. Biochem J. 400:551–561. 2006. View Article : Google Scholar
19	Cantero D, Friess H, Deflorin J, et al: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 75:388–395. 1997. View Article : Google Scholar : PubMed/NCBI
20	Wallrapp C, Hahnel S, Muller-Pillasch F, et al: A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
21	Uhland K, Siphos B, Arkona C, et al: Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int J Oncol. 35:347–357. 2009.PubMed/NCBI
22	Kilpatrick LM, Harris RL, Owen KA, et al: Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood. 108:2616–2623. 2006. View Article : Google Scholar : PubMed/NCBI
23	Min HJ, Lee Y, Zhao XF, et al: TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion. Cell Signal. 26:398–408. 2013. View Article : Google Scholar : PubMed/NCBI
24	Deer EL, Gonzalez-Hernandez J, Coursen JD, et al: Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435. 2010. View Article : Google Scholar : PubMed/NCBI
25	Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S and Real FX: New pancreas cancers cell lines that represent distinct stages of ductal differentiation. Lab Invest. 72:395–404. 1995.PubMed/NCBI
26	Noel A, Gutierrez-Fernandez A, Sounni NE, et al: New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol. 3:1402012. View Article : Google Scholar : PubMed/NCBI
27	Ochi N, Tanasanvimon S, Matsuo Y, et al: Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. J Cell Physiol. 226:1074–1081. 2011. View Article : Google Scholar : PubMed/NCBI
28	Guo XZ, Xu JH, Liu MP, et al: KAI1 inhibits anchorage-dependent and -independent pancreatic cancer cell growth. Oncol Rep. 14:59–63. 2005.PubMed/NCBI
29	Suzuki M, Kobayashi H, Kanayama N, et al: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 279:14899–14908. 2004. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Ben QW, Yao WY, et al: BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front Biosci. 17:2541–2549. 2012. View Article : Google Scholar : PubMed/NCBI
31	Touab M, Villena J, Barranco C, Arumi-Uria M and Bassols A: Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol. 160:549–557. 2002. View Article : Google Scholar : PubMed/NCBI
32	Welman A, Sproul D, Mullen P, et al: Diversity of matriptase expression level and function in breast cancer. PLoS One. 7:e341822012. View Article : Google Scholar : PubMed/NCBI
33	Jung H, Lee KP, Park SJ, et al: TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene. 27:2635–2647. 2008. View Article : Google Scholar